Literature DB >> 19208846

EVI1 Impairs myelopoiesis by deregulation of PU.1 function.

Leopoldo Laricchia-Robbio1, Kavitha Premanand, Ciro R Rinaldi, Giuseppina Nucifora.   

Abstract

EVI1 is an oncogene inappropriately expressed in the bone marrow (BM) of approximately 10% of myelodysplastic syndrome (MDS) patients. This disease is characterized by severe anemia and multilineage myeloid dysplasia that are thought to be a major cause of mortality in MDS patients. We earlier reported on a mouse model that constitutive expression of EVI1 in the BM led to fatal anemia and myeloid dysplasia, as observed in MDS patients, and we subsequently showed that EVI1 interaction with GATA1 blocks proper erythropoiesis. Whereas this interaction could provide the basis for the erythroid defects in EVI1-positive MDS, it does not explain the alteration of myeloid differentiation. Here, we have examined the expression of several genes activated during terminal myelopoiesis in BM cells and identified a group of them that are altered by EVI1. A common feature of these genes is their regulation by the transcription factor PU.1. We report here that EVI1 interacts with PU.1 and represses the PU.1-dependent activation of a myeloid promoter. EVI1 does not seem to inhibit PU.1 binding to DNA, but rather to block its association with the coactivator c-Jun. After mapping the PU.1-EVI1 interaction sites, we show that an EVI1 point mutant, unable to bind PU.1, restores the activation of PU.1-regulated genes and allows a normal differentiation of BM progenitors in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19208846     DOI: 10.1158/0008-5472.CAN-08-2562

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Histone methylation in myelodysplastic syndromes.

Authors:  Yue Wei; Irene Gañán-Gómez; Sophie Salazar-Dimicoli; Sara L McCay; Guillermo Garcia-Manero
Journal:  Epigenomics       Date:  2011-04       Impact factor: 4.778

Review 2.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

3.  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Authors:  Emilie A Bard-Chapeau; Justin Jeyakani; Chung H Kok; Julius Muller; Belinda Q Chua; Jayantha Gunaratne; Arsen Batagov; Piroon Jenjaroenpun; Vladimir A Kuznetsov; Chia-Lin Wei; Richard J D'Andrea; Guillaume Bourque; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

Review 4.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 5.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

6.  The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features.

Authors:  Marion Eveillard; Jacques Delaunay; Steven Richebourg; Laurence Lodé; Richard Garand; Soraya Wuillème; François Duhoux; Hélène Antoine-Poirel; Catherine Godon; Marie C Béné
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

7.  EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.

Authors:  Michael Wilson; Vasiliki Tsakraklides; Minh Tran; Ying-Yi Xiao; Yi Zhang; Archibald S Perkins
Journal:  J Biol Chem       Date:  2016-04-21       Impact factor: 5.157

Review 8.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

9.  CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia.

Authors:  P M Korthuis; G Berger; B Bakker; M Rozenveld-Geugien; J Jaques; G de Haan; J J Schuringa; E Vellenga; H Schepers
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

10.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.